Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Operating Officer | July 06, 2021 | July 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date July 06, 2021 · Filed July 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,790 |
Reported balance
After 2021-07-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-06 · Grant · Acquired 50,000 · Balance 124,790 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2: Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.63 · Expires 2031-07-06 | Direct | 150,000 |
Reported balance
After 2021-07-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-06 · Grant · Acquired 150,000 · Balance 150,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2: Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c).
F3: The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2020 Filed Sep 21, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $12.70 | $31,750.00 |
DisclosureSEC source: 0001567619-20-016945 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-016945 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0001567619-20-015756 · doc1.xml · derivative · entry 5 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 2,500 shares Expires 2027-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-015756 · doc1.xml · derivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,988 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 5,000 | $19.37 | $96,851.00 |
DisclosureSEC source: 0001567619-20-015756 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,556 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $19.08 to $19.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $12.70 | $31,750.00 |
DisclosureSEC source: 0001567619-20-015756 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-015756 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0001567619-20-013539 · doc1.xml · derivative · entry 5 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 12,500 shares Expires 2027-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-013539 · doc1.xml · derivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,488 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 15,000 | $18.25 | $273,687.00 |
DisclosureSEC source: 0001567619-20-013539 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,556 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $18.11 to $18.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 12,500 | $12.70 | $158,750.00 |
DisclosureSEC source: 0001567619-20-013539 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-013539 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:35 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-012458 · doc1.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,988 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:35 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 2,500 | $17.22 | $43,050.00 |
DisclosureSEC source: 0001567619-20-012458 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,556 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:35 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-012458 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:01 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-010834 · doc1.xml · derivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,488 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:01 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 2,500 | $17.17 | $42,925.00 |
DisclosureSEC source: 0001567619-20-010834 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,556 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F2 · balance_after: Includes 31,250 restricted stock units. F3 · balance_after: Includes 1,303 shares acquired on May 15, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:01 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-010834 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 31,250 restricted stock units. F3 · balance_after: Includes 1,303 shares acquired on May 15, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:01 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 593 | $17.17 | $10,181.81 |
DisclosureSEC source: 0001567619-20-010834 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,556 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F2 · balance_after: Includes 31,250 restricted stock units. F3 · balance_after: Includes 1,303 shares acquired on May 15, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 20:24 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 5,150 | $17.00 | $87,550.00 |
DisclosureSEC source: 0001567619-20-008227 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,846 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:24 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-008227 · doc1.xml · derivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,988 Underlying: Common Stock · 5,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:24 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 5,000 | $15.57 | $77,850.00 |
DisclosureSEC source: 0001567619-20-008227 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:24 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 5,000 | $2.50 | $12,502.50 |
DisclosureSEC source: 0001567619-20-008227 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · derivative · entry 7 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 2,500 shares Expires 2027-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · derivative · entry 6 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,988 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 5,000 | $21.64 | $108,190.00 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · nonDerivative · entry 5 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $21.453 to $21.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $21.64 | $54,100.00 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · nonDerivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $12.70 | $31,750.00 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $21.64 | $54,100.00 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-004436 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · derivative · entry 7 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 2,500 shares Expires 2027-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · derivative · entry 6 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,488 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $19.69 | $49,213.25 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · nonDerivative · entry 5 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $19.46 to $19.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $12.70 | $31,750.00 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · nonDerivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 5,000 | $19.56 | $97,796.00 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $19.35 to $19.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $19.57 | $48,921.25 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,996 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $19.34 to $19.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-20-001353 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001038 · doc1.xml · derivative · entry 4 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2030-01-10 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 10, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001038 · doc1.xml · nonDerivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,996 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 10 of each year, with the first 1/3 vesting on January 10, 2021 and with the RSUs being fully vested on January 10, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 31,250 RSUs. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock, $0.0001 par value | 7,146 | $17.73 | $126,698.58 |
DisclosureSEC source: 0001567619-20-001038 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,746 Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 19,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001038 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,892 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:28 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-19-023319 · doc1.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,988 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:28 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $18.69 | $46,725.00 |
DisclosureSEC source: 0001567619-19-023319 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,326 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 16 shares acquired on November 15, 2019, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:28 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-19-023319 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16 shares acquired on November 15, 2019, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:10 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-19-021759 · doc1.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,488 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:10 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $19.26 | $48,150.00 |
DisclosureSEC source: 0001567619-19-021759 · doc1.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:10 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0001567619-19-021759 · doc1.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:08 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-025608 · doc4.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,988 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:08 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $18.40 | $46,000.00 |
DisclosureSEC source: 0000899243-19-025608 · doc4.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:08 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0000899243-19-025608 · doc4.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.